EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis

Further Publications Rheumatology

Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies

Ann Rheum Dis

Siddle HJ, Chapman LS, Mankia K, Zăbălan C, Kouloumas M, Raza K, Falahee M, Kerry J, Kerschbaumer A, Aletaha D, Emery P, Richards SH

doi: 10.1136/annrheumdis-2021-221160

Further Publications Rheumatology

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis

Ann Rheum Dis

Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Pchelnikova P, Blaas E, Senolt L, Szekanecz Z, Choy EH, Dougados M, Jacobs JW, Geenen R, Bijlsma JW, Zink A, Aletaha D, Schoneveld L, van Riel P, Dumas S, Prior Y, Nikiphorou E, Ferraccioli G, Schett G, Hyrich KL, Mueller-Ladner U, Buch MH, McInnes IB, van der Heijde D, van Laar JM

doi: 10.1136/annrheumdis-2021-220973

Rheumatoid Arthritis

Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data

Arthritis Res Ther

Simon TA, Dong L, Winthrop KL

doi: 10.1186/s13075-020-02399-2

Rheumatoid Arthritis

Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study

Clin Rheumatol.

Gaubitz M, Göttl KH, Behmer O, Lippe R, Meng T, Löschmann PA

doi: 10.1007/s10067-017-3757-8.

Juvenile Idiopathic ArthritisPsoriatic ArthritisRheumatoid ArthritisSpinal Disorders

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial

BMJ

Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R, NORD-STAR study group.

doi: 10.1136/bmj.m4328

Juvenile Idiopathic ArthritisRheumatoid ArthritisSpinal Disorders

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial

Arthritis Res Ther

Stockfelt M, Lundell AC, Hetland ML, Østergaard M, Uhlig T, Heiberg MS, Haavardsholm EA, Nurmohamed MT, Lampa J, Nordström D, Petersen KH, Gudbjornsson B, Gröndal G, Aldridge J, Andersson K, Blennow K, Zetterberg H, van Vollenhoven R, Rudin A

doi: 10.1186/s13075-021-02556-1

Rheumatoid Arthritis

Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study

Arthritis Res Ther.

Ruscitti P, Cipriani P, Liakouli V, Iacono D, Pantano I, Margiotta DPE, Navarini L, Destro Castaniti GM, Maruotti N, Di Scala G, Picciariello L, Caso F, Bongiovanni S, Grembiale RD, Atzeni F, Scarpa R, Perosa F, Emmi G, Cantatore FP, Guggino G, Afeltra A, Ciccia F, Giacomelli R

doi: 10.1186/s13075-019-1975-y.

Rheumatoid Arthritis

2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis

Ann Rheum Dis.

Radner H, Chatzidionysiou K, Nikiphorou E, Gossec L, Hyrich KL, Zabalan C, van Eijk-Hustings Y, Williamson PR, Balanescu A, Burmester GR, Carmona L, Dougados M, Finckh A, Haugeberg G, Hetland ML, Oliver S, Porter D, Raza K, Ryan P, Santos MJ, van der Helm-van Mil A, van Riel P, von Krause G, Zavada J, Dixon WG, Askling J

doi: 10.1136/

Rheumatoid Arthritis

Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study

Rheumatology (Oxford).

de Germay S, Bagheri H, Despas F, Rousseau V, Montastruc F

doi: 10.1093/rheumatology/kez604.

Related content

Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis

Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data

Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial

Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study

2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis

Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study